Brief: Tonix Pharmaceuticals Announces That Its Single Dose Mpox Vaccine Candidate Tnx-801 Aligns With Who's Newly Issued Preferred Target Product Profile For Mpox Vaccines In Global Health Emergency
16/09/2024 12:37
Sept 16 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS ANNOUNCES THAT ITS SINGLE DOSE MPOX
VACCINE CANDIDATE TNX-801 ALIGNS WITH WHO’S NEWLY ISSUED
PREFERRED TARGET PRODUCT PROFILE FOR MPOX VACCINES IN GLOBAL
HEALTH EMERGENCY
Source text for Eikon: ID:nGNXc2KDVY
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview